D69.51 vs T80.82XS
D69.51 (Posttransfusion purpura) compared with T80.82XS (Complication of immune effector cellular therapy, sequela), from the official CMS tabular data. Both may be reported when both conditions are documented (Excludes2).
Can these codes be reported together?
Yes, when both are documented. T80.82XS carries an Excludes2 note covering D69.51: “posttransfusion purpura (D69.51)”
Excludes2 marks distinct conditions — both may be reported when both are documented.
Side by side
| D69.51Posttransfusion purpura | T80.82XSComplication of immune effector cellular therapy, sequela | |
|---|---|---|
| Billing status | Billable | Billable |
| Classification | D50-D89 — Diseases of the Blood and Blood-forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89) | S00-T88 — Injury, Poisoning and Certain Other Consequences of External Causes (S00-T88) |
| Definition | Posttransfusion purpura is a billable ICD-10-CM diagnosis code (D69.51). | Complication of immune effector cellular therapy, sequela is a billable ICD-10-CM diagnosis code (T80.82S). |
| 7th character | — | The appropriate 7th character is to be added to each code from category T80 |
| Includes | Posttransfusion purpura from whole blood (fresh) or blood products PTP | complications following perfusion Complication of chimeric antigen receptor (CAR-T) cell therapy Complication of IEC therapy |
| Use additional code | — | code to identify the specific complication, such as: cytokine release syndrome (D89.83-) immune effector cell-associated neurotoxicity syndrome (G92.0-) |
Derived from the official CMS ICD-10-CM tabular data (FY2026). Not billing advice; verify sequencing rules for the encounter. All data sources